Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 5.11
NEPT's Cash to Debt is ranked higher than
67% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NEPT: 5.11 )
NEPT' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 5.11

Equity to Asset 0.61
NEPT's Equity to Asset is ranked higher than
67% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NEPT: 0.61 )
NEPT' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.83
Current: 0.61

-0.42
0.83
F-Score: 3
Z-Score: 1.77
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -112.41
NEPT's Operating margin (%) is ranked higher than
68% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NEPT: -112.41 )
NEPT' s 10-Year Operating margin (%) Range
Min: -116.18   Max: -9.17
Current: -112.41

-116.18
-9.17
Net-margin (%) -85.35
NEPT's Net-margin (%) is ranked higher than
70% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NEPT: -85.35 )
NEPT' s 10-Year Net-margin (%) Range
Min: -156.23   Max: -10.08
Current: -85.35

-156.23
-10.08
ROE (%) -32.95
NEPT's ROE (%) is ranked higher than
67% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -20.84 vs. NEPT: -32.95 )
NEPT' s 10-Year ROE (%) Range
Min: -490   Max: -6.94
Current: -32.95

-490
-6.94
ROA (%) -16.28
NEPT's ROA (%) is ranked higher than
72% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NEPT: -16.28 )
NEPT' s 10-Year ROA (%) Range
Min: -89.09   Max: -4.31
Current: -16.28

-89.09
-4.31
ROC (Joel Greenblatt) (%) -39.81
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
79% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -247.50 vs. NEPT: -39.81 )
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -962.99   Max: -11.1
Current: -39.81

-962.99
-11.1
Revenue Growth (%) -7.90
NEPT's Revenue Growth (%) is ranked higher than
70% of the 624 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NEPT: -7.90 )
NEPT' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 32
Current: -7.9

0
32
EBITDA Growth (%) 230.20
NEPT's EBITDA Growth (%) is ranked higher than
100% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NEPT: 230.20 )
NEPT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 230.2
Current: 230.2

0
230.2
EPS Growth (%) 89.00
NEPT's EPS Growth (%) is ranked higher than
99% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NEPT: 89.00 )
NEPT' s 10-Year EPS Growth (%) Range
Min: -47.7   Max: 97.9
Current: 89

-47.7
97.9
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

NEPT Guru Trades in

Q3 2012

NEPT Guru Trades in Q3 2012

Steven Cohen 12,967 sh (New)
» More
Q4 2012

NEPT Guru Trades in Q4 2012

Steven Cohen Sold Out
» More
Q1 2014

NEPT Guru Trades in Q1 2014

Jim Simons 20,200 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NEPT



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
NEPT's P/B is ranked higher than
87% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 5.80 vs. NEPT: 2.40 )
NEPT' s 10-Year P/B Range
Min: 1.97   Max: 48
Current: 2.4

1.97
48
P/S 9.17
NEPT's P/S is ranked higher than
80% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 18.96 vs. NEPT: 9.17 )
NEPT' s 10-Year P/S Range
Min: 0.91   Max: 33.87
Current: 9.17

0.91
33.87
EV-to-EBIT -6.67
NEPT's EV-to-EBIT is ranked higher than
53% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NEPT: -6.67 )
NEPT' s 10-Year EV-to-EBIT Range
Min: 90.6   Max: 1664.6
Current: -6.67

90.6
1664.6
Current Ratio 5.04
NEPT's Current Ratio is ranked higher than
77% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NEPT: 5.04 )
NEPT' s 10-Year Current Ratio Range
Min: 0.4   Max: 5.93
Current: 5.04

0.4
5.93
Quick Ratio 3.97
NEPT's Quick Ratio is ranked higher than
75% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. NEPT: 3.97 )
NEPT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 4.87
Current: 3.97

0.2
4.87

Valuation & Return

vs
industry
vs
history
Price/Net Cash 75.30
NEPT's Price/Net Cash is ranked higher than
72% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 63.00 vs. NEPT: 75.30 )
NEPT' s 10-Year Price/Net Cash Range
Min: 5.43   Max: 385
Current: 75.3

5.43
385
Price/Net Current Asset Value 9.40
NEPT's Price/Net Current Asset Value is ranked higher than
82% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 43.44 vs. NEPT: 9.40 )
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 4.81   Max: 350
Current: 9.4

4.81
350
Price/Tangible Book 2.40
NEPT's Price/Tangible Book is ranked higher than
91% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 8.86 vs. NEPT: 2.40 )
NEPT' s 10-Year Price/Tangible Book Range
Min: 2.59   Max: 40.71
Current: 2.4

2.59
40.71
Price/Median PS Value 1.20
NEPT's Price/Median PS Value is ranked higher than
78% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NEPT: 1.20 )
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 9
Current: 1.2

0.12
9
Earnings Yield (Greenblatt) 0.20
NEPT's Earnings Yield (Greenblatt) is ranked lower than
64% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. NEPT: 0.20 )
NEPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.1
Current: 0.2

0.1
1.1
Forward Rate of Return (Yacktman) -2.91
NEPT's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -10.93 vs. NEPT: -2.91 )
NEPT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -5.4   Max: -2.7
Current: -2.91

-5.4
-2.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTB.Canada, NTU.Germany
Neptune Technologies & Bioressources Inc. was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine‐derived omega‐3 polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company produces omega‐3 PUFAs through its patented process of extracting oils from Antartic krill, which omega‐3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its lead products, include Neptune Krill Oil (NKO) and ECOKRILL Oil (EKOTM), generally come in capsule form and serve as a dietary supplement to consumers. The Company has three reportable segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune), the second is the development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti) and the third is the development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm).
» More Articles for NAS:NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Acasti Announces First Quarter Results Jul 15 2014
Neptune Announces First Quarter Results Jul 15 2014
Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials Jul 09 2014
Neptune to Hold Conference Call to Discuss First Quarter Results Jul 08 2014
Neptune Receives Composition Patent in Australia Jun 23 2014
NeuroBioPharm Reports Results of Annual General Meeting Jun 20 2014
Neptune Reports Results of Annual and Special Meeting Jun 20 2014
Neptune Sherbrooke Plant to Resume Production Jun 13 2014
Has Enzymotec Been Over-Punished? Jun 09 2014
NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Financials Jun 06 2014
Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer May 30 2014
High option volume stocks May 28 2014
Neptune Technologies appoints Andre Godin as interim CEO May 23 2014
Neptune, Acasti and NeuroBioPharm Announce Appointment of Interim CEO May 23 2014
Neptune Technologies reports Q4 revenue $3.67M, consensus $7.08M May 21 2014
Neptune Announces Fourth Quarter and Fiscal Year Results May 21 2014
NeuroBioPharm Announces Resignation of Chief Financial Officer May 20 2014
Neptune Announces Proposed Director Nominees for Its Upcoming Annual General Meeting May 16 2014
Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year Results May 13 2014
Neptune Technologies says CSST report attributes some responsibility to company May 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide